Literature DB >> 12384149

Isolation and expansion of human cytomegalovirus- specific cytotoxic T lymphocytes using interferon-gamma secretion assay.

Alfred Lennart Bissinger1, Georg Rauser, Holger Hebart, Friederike Frank, Gerhard Jahn, Hermann Einsele.   

Abstract

OBJECTIVE: The aim of this study was to isolate and expand donor-derived human cytomegalovirus (HCMV)-specific cytotoxic T lymphocytes (CTLs) for adoptive transfer of 10(7) cells per m(2) of body surface area to restore protective immunity after stem cell transplantation.
MATERIALS AND METHODS: A new strategy to generate HCMV-specific CTLs using the interferon-gamma (IFN-gamma) secretion assay, followed by expansion to numbers sufficient for clinical application with interleukin-2 and feeder cell stimulation, is described.
RESULTS: From 1 to 5 x 10(4) HCMV peptide-specific T lymphocytes (greater than 90% CD3(+)CD8(+)) were isolated from 1 to 2 x 10(8) peripheral blood mononuclear cells comparable to 50 to 100 mL of blood from HLA-A*0201 HCMV seropositive blood donors (n = 14) and expanded ex vivo after a median of 16 days (range 8-28 days; n = 13) to greater than 10(7)/m(2) HCMV peptide-specific CTLs using autologous (n = 2) or allogeneic (n = 11) feeder cell stimulation. In three experiments, expansion to 6 weeks was performed, achieving a median of 1.6 x 10(9) cells (range 6.1 x 10(8)-3.3 x 10(9)). Characterization of these HCMV-specific CTL lines revealed an average purity of 89.2% (range 66.2-99.3%) using HCMV pp65 peptide HLA-A*0201 tetramer staining (n = 14) and 89.4% (range 64.4-99.5%) by peptide-specific IFN-gamma secretion (n = 7). A median of 82.6% (range 76.0-88.0%) showed perforin secretion (n = 3) and 57.5% (range 22.2-80.7%) specific lysis of peptide-pulsed T2 cells (n = 5). A median of 52.2% (range 35.2-7.3%) revealed specific killing of HCMV-infected autologous, but not allogeneic, fibroblasts (n = 6).
CONCLUSIONS: IFN-gamma secretion assay allows development of a simple and rapid protocol with short expansion times for generation of greater than 10(7)/m(2) HCMV-specific CTLs for adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384149     DOI: 10.1016/s0301-472x(02)00897-4

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  4 in total

1.  Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells.

Authors:  Inge Jedema; Marian van de Meent; Jeanette Pots; Michel G D Kester; Martha T van der Beek; J H Frederik Falkenburg
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

Review 2.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

3.  Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.

Authors:  Yuriko Fujita; Ann M Leen; Jiali Sun; Yozo Nakazawa; Eric Yvon; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

4.  CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers.

Authors:  Lorea Beloki; Miriam Ciaurriz; Cristina Mansilla; Amaya Zabalza; Estela Perez-Valderrama; Edward R Samuel; Mark W Lowdell; Natalia Ramirez; Eduardo Olavarria
Journal:  J Transl Med       Date:  2014-11-19       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.